Lawrence Mitchell G, Porter Laura H, Clouston David, Murphy Declan G, Frydenberg Mark, Taylor Renea A, Risbridger Gail P
Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.
Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Sci Transl Med. 2020 Mar 4;12(533). doi: 10.1126/scitranslmed.aaz0152.
Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.
前列腺癌是一种常见的恶性肿瘤，但只有部分肿瘤具有致命性。准确识别这些肿瘤将改善临床实践并指导研究。侵袭性癌症通常具有独特的病理特征，包括前列腺导管内癌（IDC-P）和导管腺癌。在此，我们回顾这些病理特征的重要性，因为它们常常被忽视，尤其是在基因组学和临床前检测中。病理学、基因组学以及患者来源模型表明，IDC-P和导管腺癌伴随着多种预后不良的标志物。因此，“了解正在生长的是什么”将有助于将临床前研究转化为在临床上精准定位和治疗高危前列腺癌。
